Lp(a): The Hidden Cholesterol Risk 1 in 5 People May Have

What exactly is Lp(a)?

Think of Lp(a) as a close relative of LDL.

Like LDL, it carries cholesterol through your bloodstream. But Lp(a) has an additional protein attached to it called apolipoprotein(a), or apo(a).

That extra protein is what makes Lp(a) different.

Researchers have linked elevated Lp(a) to processes that can promote plaque buildup in arteries, inflammation, and potentially impaired breakdown of blood clots.

In other words, Lp(a) isn’t simply another way of measuring LDL. It’s a separate cardiovascular risk factor.

And that’s important because your regular cholesterol test may not tell you what your Lp(a) level is.

Why can Lp(a) be dangerous?

The simplest way to understand the difference is to think about the multiple ways elevated Lp(a) may contribute to cardiovascular risk.

1. Plaque buildup

Lp(a) carries cholesterol and can contribute to its accumulation in artery walls.

2. Inflammation

Lp(a) carries oxidized phospholipids, molecules that can contribute to inflammation within the blood vessel wall.

3. Clot breakdown

The apo(a) portion of Lp(a) resembles a protein involved in the body’s clot-dissolving system. Lp(a) may interfere with the body’s ability to break down blood clots.

That’s why elevated Lp(a) has attracted so much attention in cardiovascular research. It isn’t just about the amount of cholesterol in your blood. It’s about the characteristics of the particle carrying it.

The biggest surprise: you didn’t cause your Lp(a) level

Here’s where Lp(a) gets very different from the cholesterol numbers you’re probably more familiar with.

Your Lp(a) level is mostly determined by your genes. The research brief estimates that roughly 70% to 90% of Lp(a) levels are genetically determined, with levels generally becoming stable relatively early in life.

That means the usual advice doesn’t work the same way here.

Diet?

Eating healthier is still important for your heart, but changing your diet generally doesn’t meaningfully lower Lp(a).

Exercise?

Exercise is extremely valuable for cardiovascular health, but it generally doesn’t lower the Lp(a) number itself.

Statins?

This one is especially important. Statins are highly effective at lowering LDL cholesterol and reducing cardiovascular risk. But they aren’t designed to lower Lp(a).

So if someone takes a statin and still has elevated Lp(a), that doesn’t mean the medication failed. It means they’re dealing with another risk factor that LDL-lowering treatment wasn’t designed to target.

That’s an important distinction.

Don’t stop or change prescribed cholesterol medication because of a high Lp(a) result. Talk with the healthcare professional managing your treatment.

You won’t find Lp(a) on most standard cholesterol tests

This is one of the biggest reasons Lp(a) can remain hidden. A standard lipid panel typically gives you numbers such as:

• • Total cholesterol
  • LDL cholesterol
  • HDL cholesterol
  • Triglycerides

But Lp(a) requires its own blood test. It isn’t automatically included in a routine cholesterol panel.

So you can have what appears to be a fairly ordinary cholesterol panel and still have an elevated Lp(a) level.

That’s why the question isn’t simply: “What’s my cholesterol?” It may also be worth asking: “Have I ever had my Lp(a) tested?”

How common is elevated Lp(a)?

This is where the numbers get surprising. About 1 in 5 people may have elevated Lp(a).

Yet testing remains rare. Large healthcare datasets have found Lp(a) testing rates generally below 1%, with one U.S. cohort finding testing in only about 0.3% of more than 5.5 million patients.

That’s a remarkable gap:

• • Common risk factor.
  • Uncommon test.

And because Lp(a) is largely inherited, an elevated result can have implications for your family too.

Who should consider an Lp(a) test?

Because Lp(a) is largely inherited and relatively stable, many current guidelines favor testing at least once in adulthood rather than repeatedly checking the same number. Exact recommendations can vary by organization.

Testing may be particularly relevant if you have:

• • A family history of premature heart disease or stroke
  • A close relative with elevated Lp(a)
  • A personal history of cardiovascular disease, particularly at a younger age
  • High LDL cholesterol that doesn’t respond as expected to treatment
  • Other cardiovascular risk factors that don’t fully explain your risk

If a parent, sibling, or child has elevated Lp(a), that is also worth discussing with your healthcare professional. Because Lp(a) is inherited, first-degree relatives have roughly a 50% chance of carrying an elevated level.

What does your Lp(a) number mean?

Lp(a) can be reported in mg/dL or nmol/L. You’ll often see results roughly grouped into three ranges:

Lower

<30 mg/dL
<75 nmol/L

Intermediate

30–50 mg/dL
75–125 nmol/L

High

≥50 mg/dL
≥125 nmol/L

These ranges are useful for communicating risk, but don’t think of them as a simple “safe vs. dangerous” switch. Lp(a)-associated cardiovascular risk increases across a continuum, and cutoffs can vary somewhat among guidelines.

Also, don’t try to convert mg/dL to nmol/L using a simple fixed multiplier. The relationship isn’t that straightforward because Lp(a) particles can vary in size. Most importantly, your Lp(a) number shouldn’t be interpreted in isolation. Your LDL cholesterol, blood pressure, blood sugar, smoking status, family history and other risk factors all contribute to your overall cardiovascular risk.

Lp(a) levels can vary across populations

Research has found meaningful differences in median Lp(a) levels among population groups.

For example, in the Multi-Ethnic Study of Atherosclerosis (MESA), median Lp(a) was:

• • Black: 35.1 mg/dL
  • Hispanic: 13.1 mg/dL
  • White: 12.9 mg/dL
  • Chinese American: 12.9 mg/dL

But there’s an important caveat. These are population-level medians, not predictions about an individual person. Your ancestry does not determine your personal Lp(a) result. And the testing picture is interesting too. In a separate large U.S. cohort, among people who actually received an Lp(a) test, 65.9% were White, 8.6% were Asian, 3.2% were Black, and 8.9% were Hispanic or Latino.

These studies use different population classifications and come from different cohorts, so the numbers shouldn’t be treated as a direct head-to-head comparison. But they illustrate a broader issue: Lp(a) testing remains uneven across populations.

So what can you actually do about high Lp(a)?

This is where the conversation becomes more useful. You can’t currently “out-exercise” a genetically elevated Lp(a) level.

But that doesn’t mean you’re powerless. An elevated Lp(a) result is a reason to take your overall cardiovascular risk more seriously. That can include working with your healthcare professional to:

• • Keep LDL cholesterol under control. Even though LDL treatment doesn’t lower Lp(a), lowering LDL remains an important way to reduce cardiovascular risk.
  • Manage blood pressure.
  • Don’t smoke.
  • Stay physically active.
  • Pay attention to blood sugar and other cardiovascular risk factors.
  • Discuss your Lp(a) result in the context of your complete health picture.

And because Lp(a) is inherited, consider discussing family testing with your healthcare professional. The goal isn’t to obsess over one number. It’s to find out whether there is a piece of your cardiovascular risk that you didn’t know was there.

What about the cost of an Lp(a) test?

If you’re in the U.S., the answer depends heavily on where you get tested and what insurance plan you have.

A 2024 review cited in your research brief found direct cash prices at commercial U.S. laboratories ranging from roughly $39 to $177 per test. Insurance coverage is inconsistent and continues to evolve. Some commercial insurers may cover testing when there’s a clear clinical reason, such as a family history of premature cardiovascular disease or an existing cardiovascular event. Coverage can vary by plan, so it’s worth checking with your insurer and healthcare provider before ordering the test.

Because this is usually a one-time test, the conversation with your healthcare professional can be especially worthwhile.

Lp(a) isn’t the cholesterol number most people are watching

For decades, the cholesterol conversation has largely centered on LDL. That’s still important. But cardiovascular risk is more complicated than one number on a lab report. Lp(a) adds another piece to the puzzle.

• • It’s common.
  • It’s largely inherited.
  • It can remain hidden on a standard cholesterol panel.
  • And many people who have it have never been tested.

The good news is that knowing your Lp(a) level gives you information you didn’t have before. And information can change the conversation you have with your healthcare professional.

The question to ask may be simple: “Have I ever had my Lp(a) checked?”

A note on emerging Lp(a) treatments

Researchers are actively developing treatments designed specifically to lower Lp(a), including RNA-targeted therapies such as antisense oligonucleotides and siRNA drugs. Several have reached late-stage clinical trials. But these treatments should not be presented as today’s solution. The research brief notes that the therapies discussed are still in clinical development and were not yet approved at the time of the research.

For now, the most useful step is much simpler:

Know your number. Understand what it means. And discuss it with a healthcare professional.

Sources:

• Kronenberg F, Mora S, Stroes ESG, et al.
  Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. 2022;43:3925–3946.
  European Atherosclerosis Society consensus statement
• Wilson DP, et al. / National Lipid Association.
  Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come. Journal of Clinical Lipidology.
  NLA Lp(a) clinical guidance
• NHLBI Working Group.
  Lipoprotein(a) and Cardiovascular Disease — 2018 NHLBI Working Group report.
  This is the source behind the commonly cited ~20% / 1 in 5 prevalence framing.
• MESA — Multi-Ethnic Study of Atherosclerosis.
  Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis.
• Bhatia HS, Hurst S, Desai P, Zhu W, Yeang C.
  Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States. Journal of the American Heart Association. 2023;12:e031255.
  This is particularly important for your infographic because it supports the 0.3% overall testing rate and your race/ethnicity testing graphic.
  Full Bhatia et al. study
• Trends and disparities in lipoprotein(a) testing in a large integrated US health system, 2000–23.
  European Journal of Preventive Cardiology. 2024.
  Useful as an additional, more recent source on disparities and trends in Lp(a) testing.
  Full study
• Lipoprotein(a) Testing Patterns in a Large Health System.
  This earlier health-system study examined who was receiving Lp(a) testing and found that testing was particularly associated with patients with prior cardiovascular disease or premature events.
  PubMed study
• American Family Physician.
  Diagnostic Tests for Atherosclerotic Cardiovascular Disease. 2024.
  This is the source used in your research brief for the approximate $39–$177 U.S. cash-price range and the discussion of insurance coverage.
• American Journal of Managed Care (AJMC).
  Recent reporting/interviews concerning Lp(a) reimbursement and insurance coverage trends.
• UnitedHealthcare Medicare Advantage reimbursement policy documentation.
  Used in the research brief for the specific Medicare Advantage coverage example.